RadPharm provides end-to-end imaging solutions for clinical trials research from early stage through Phase IV studies. Our early phase services allow trial sponsors to make critical go/no-go decisions faster. This facilitates the sponsor’s goal of identifying the most promising compounds for further consideration from compounds which do not demonstrate imaging evidence of efficacy.
Utilizing advanced, validated image analysis technology, RadPharm’s in-house radiologists and nuclear medicine physicians quantitatively and qualitatively evaluate data from traditional modalities including FDG-Positron Emission Tomography (PET) and PET/ CT as well as novel imaging methods and markers. Similar to the process used for anatomical image interpretations, all physiological response assessments are defined by a unique medical imaging charter which follows defined quality guidelines. This process provides high confidence in the data output you receive, based on the imaging-based trial endpoints chosen.
Benefits include:
- Accurate physiological response measurements
- Quicker decision making capabilities
- Smaller clinical trials with fewer patients
- Maximized statistical power
- Reduced associated costs
Make go/no go decisions earlier, contact RadPharm today at 609-936-2600. |
